Dipòsit Digital de Documents de la UAB 23 registres trobats  1 - 10següentfinal  anar al registre: La cerca s'ha fet en 0.02 segons. 
1.
6 p, 754.7 KB Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer : a post hoc analysis of the MOSAIC trial / Auclin, Edouard (Bourgogne Franche-Comté University, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France) ; André, Thierry (Oncology Multidisciplinary Research Group (GERCOR)) ; Taieb, Julien (UMR-S 1147, INSERM) ; Banzi, Maria (Unit of Medical Oncology, Clinical Cancer Center, AUSL-IRCCS Reggio Emilia, Reggio Emilia, Italy) ; Van Laethem, Jean-Luc (Université Libre de Bruxelles. Department of Gastroenterology and Digestive diseases, Hopital Erasme) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Hickish, Tamas (Royal Bournemouth Hospital and Bournemouth University. Department of Oncology) ; de Gramont, Aimery (Institut Hospitalier Franco-Britannique. Department of Oncology) ; Vernerey, Dewi (Oncology Multidisciplinary Research Group (GERCOR)) ; Universitat Autònoma de Barcelona
Adjuvant treatment for stage II colon cancer (CC) can be proposed to patients with high-risk disease. Recently, 2. 35 ng/mL carcinoembryonic antigen (CEA) was identified as the best cut-off value. This post hoc analysis of the MOSAIC trial assessed post-operative CEA prognostic value for survival outcomes and predictive value for the addition of oxaliplatin to adjuvant treatment. [...]
2019 - 10.1038/s41416-019-0521-7
British Journal of Cancer, Vol. 121 (july 2019) , p. 312-317  
2.
4 p, 972.8 KB Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma : implications for biomarker-driven clinical trials / Montal, R. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Andreu-Oller, C. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Bassaganyas, L. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Esteban-Fabró, R. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Moran, Sebastian (Institut d'Investigació Biomèdica de Bellvitge) ; Montironi, C. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Moeini, A. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Pinyol, R. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Peix, J. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Cabellos, L. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Villanueva, A. (Liver Cancer Program. Division of Liver Diseases. Icahn School of Medicine at Mount Sinai) ; Sia, D. (Liver Cancer Program. Division of Liver Diseases. Icahn School of Medicine at Mount Sinai) ; Mazzaferro, V. (University of Milan and Gastrointestinal Surgery and Liver Transplantation Unit. Fondazione IRCCS. Istituto Nazionale dei Tumori) ; Esteller, M. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Llovet, J.M. (Institució Catalana de Recerca i Estudis Avançats (ICREA)) ; Universitat Autònoma de Barcelona
The clinical utility of serum alpha-fetoprotein (AFP) in patients with hepatocellular carcinoma (HCC) is widely recognised. However, a clear understanding of the mechanisms of AFP overexpression and the molecular traits of patients with AFP-high tumours are not known. [...]
2019 - 10.1038/s41416-019-0513-7
British Journal of Cancer, Vol. 121 Núm. 4 (13 2019) , p. 340-343  
3.
6 p, 332.7 KB Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype / Páez, David (Institut d'Investigació Biomèdica Sant Pau) ; Tobeña, María (Institut d'Investigació Biomèdica Sant Pau) ; Fernández-Plana, Julen (Hospital Universitario Mutua Terrassa. Medical Oncology Department) ; Sebio, Ana (Institut d'Investigació Biomèdica Sant Pau) ; Virgili, Anna C. (Institut d'Investigació Biomèdica Sant Pau) ; Cirera, Lluís (Hospital Universitario Mutua Terrassa. Medical Oncology Department) ; Barnadas, Agustí (Institut d'Investigació Biomèdica Sant Pau) ; Riera, Pau (Institut d'Investigació Biomèdica Sant Pau) ; Sullivan, Ivana (Institut d'Investigació Biomèdica Sant Pau) ; Salazar, Juliana (Institut d'Investigació Biomèdica Sant Pau) ; Universitat Autònoma de Barcelona
Patients harbouring the UGT1A1 *28/*28 genotype are at risk of severe toxicity with the standard irinotecan dose. However, this dose is considerably lower than the dose that can be tolerated by UGT1A1 *1/*1 and *1/*28 patients. [...]
2018 - 10.1038/s41416-018-0348-7
British Journal of Cancer, Vol. 120 (december 2018) , p. 190-195  
4.
15 p, 1.5 MB Mutant p53 blocks SESN1/AMPK/PGC-1α/UCP2 axis increasing mitochondrial O· production in cancer cells / Cordani, Marco (Universidad Autónoma de Madrid. Instituto de Investigaciones Biomédicas "Alberto Sols") ; Butera, Giovanna (University of Verona. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry) ; Dando, Ilaria (University of Verona. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry) ; Torrens-Mas, Margalida (Hospital Universitario Son Espases. Instituto de Investigación Sanitaria de Palma (IdISPa)) ; Butturini, Elena (University of Verona. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry) ; Pacchiana, Raffaella (University of Verona. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry) ; Oppici, Elisa (University of Verona. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry) ; Cavallini, Chiara (University of Verona. Research Center LURM (Interdepartmental Laboratory of Medical Research)) ; Gasperini, Sara (Section of General Pathology, University of Verona. Department of Medicine) ; Tamassia, Nicola (Section of General Pathology, University of Verona. Department of Medicine) ; Nadal-Serrano, Mercedes (Vall d'Hebron Institut d'Oncologia) ; Coan, Michela (CRO National Cancer Institute Aviano. Division of Molecular Oncology, Department of Translational Research) ; Rossi, Davide (Institute of Oncology Research) ; Gaidano, Gianluca (University of Eastern Piedmont. Division of Hematology, Department of Translational Medicine) ; Caraglia, Michele (Department of Biochemistry, Biophysics and General Pathology, University of Campania "L. Vanvitelli", Naples, Italy) ; Mariotto, Sofia (University of Verona. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry) ; Spizzo, Riccardo (CRO National Cancer Institute Aviano. Division of Molecular Oncology, Department of Translational Research) ; Roca, Pilar (Hospital Universitario Son Espases. Instituto de Investigación Sanitaria de Palma (IdISPa)) ; Oliver, Jordi (Hospital Universitario Son Espases. Instituto de Investigación Sanitaria de Palma (IdISPa)) ; Scupoli, Maria Teresa (University of Verona. Research Center LURM (Interdepartmental Laboratory of Medical Research)) ; Donadelli, Massimo (University of Verona. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry) ; Universitat Autònoma de Barcelona
The TP53 tumor suppressor gene is the most frequently altered gene in tumors and mutant p53 gain-of-function isoforms actively promote cancer malignancy. A panel of wild-type and mutant p53 cancer cell lines of different tissues, including pancreas, breast, skin, and lung were used, as well as chronic lymphocytic leukemia (CLL) patients with different TP53 gene status. [...]
2018 - 10.1038/s41416-018-0288-2
British Journal of Cancer, Vol. 119 (october 2018) , p. 994-1008  
5.
7 p, 1.3 MB Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer / Melisi, Davide (University of Verona, Piazzale Ludovico Antonio Scuro) ; Garcia-Carbonero, Rocio (Oncology Department, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), UCM, CNIO, CIBERONC, Madrid, Spain) ; Macarulla, Teresa (Vall d'Hebron Institut d'Oncologia) ; Pezet, Denis (Centre Hospitalier Universitaire) ; Deplanque, Gael (Hôpital Riviera-Chablais) ; Fuchs, Martin (Klinikum Bogenhausen, Städtisches Klinikum München GmbH, Englschalkinger Road 77, 81925 Munich, Germany) ; Trojan, Jorg (Goethe University Medical Center) ; Oettle, Helmut (Onkologische und Hämatologische Schwerpunktpraxis, Friedrichshafen, Germany) ; Kozloff, Mark (Ingalls Memorial Hospital) ; Cleverly, Ann (Eli Lilly and Company, Erl Wood Manor, Windlesham) ; Smith, Claire (formerly of Eli Lilly and Company) ; Estrem, Shawn T. (Eli Lilly and Company, Lilly Corporate Center) ; Gueorguieva, Ivelina (Eli Lilly and Company, Erl Wood Manor, Windlesham) ; Lahn, Michael M. F. (Wisconsin Ave., #8008, Bethesda, MD 20815 USA) ; Blunt, Al (Advaxis, Inc) ; Benhadji, Karim A. (Eli Lilly and Company) ; Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ; Universitat Autònoma de Barcelona
Galunisertib is the first-in-class, first-in-human, oral small-molecule type I transforming growth factor-beta receptor (ALK5) serine/threonine kinase inhibitor to enter clinical development. The effect of galunisertib vs. [...]
2018 - 10.1038/s41416-018-0246-z
British Journal of Cancer, Vol. 119 (october 2018) , p. 1208-1214  
6.
7 p, 549.5 KB Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma / Powles, Thomas (University of London. Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust, Queen Mary) ; Motzer, Robert J. (Memorial Sloan Kettering Cancer Center) ; Escudier, Bernard (Gustave Roussy) ; Pal, Sumanta (City of Hope National Medical Center) ; Kollmannsberger, Christian (BCCA Vancouver Cancer Centre. British Columbia Cancer Agency) ; Pikiel, Joanna (Wojewodzkie Centrum Onkologii, 80-219 Gdańsk, Poland) ; Gurney, Howard (Macquarie University. Macquarie University and Westmead Hospital) ; Rha, Sun Young (Yonsei Cancer Center. Severance Hospital) ; Park, Se Hoon (Samsung Medical Center) ; Geertsen, Poul F. (Copenhagen University. Herlev and Gentofte Hospital, Herlev Hospital) ; Gross-Goupil, Marine (Groupe Hospitalier Saint André, 33000 Bordeaux, France) ; Grande, Enrique (Hospital Universitario Ramón y Cajal) ; Suarez, Cristina (Vall d'Hebron Institut d'Oncologia) ; Markby, David W. (Exelixis, Inc) ; Arroyo, Alan (Exelixis, Inc) ; Dean, Mark (Exelixis, Inc) ; Choueiri, Toni K. (Dana-Farber Cancer Institute) ; George, Daniel (Duke University Medical Center) ; Universitat Autònoma de Barcelona
In the phase 3 METEOR trial, cabozantinib improved progression-free survival (PFS), objective response rate (ORR), and overall survival (OS) versus everolimus in patients with advanced renal cell carcinoma (RCC), after prior antiangiogenic therapy. [...]
2018 - 10.1038/s41416-018-0164-0
British Journal of Cancer, Vol. 119 (september 2018) , p. 663-669  
7.
7 p, 434.6 KB SCOT : a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer / Robles-Zurita, José (University of Glasgow. Institute of Health and Wellbeing) ; Boyd, Kathleen A. (University of Glasgow. Institute of Health and Wellbeing) ; Briggs, Andrew H. (University of Glasgow. Institute of Health and Wellbeing) ; Iveson, Timothy (Southampton University Hospital NHS Foundation Trust) ; Kerr, Rachel S. (University of Oxford. Department of Oncology) ; Saunders, Mark P. (The Christie Hospital) ; Cassidy, Jim (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences) ; Hollander, Niels Henrik (Zealand University Hospital, Department of Oncology and Palliative Care, Rǻdmandsengen 5) ; Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ; Segelov, Eva (Australasian Gastro-Intestinal Trials Group (AGITG) and Monash University and Monash Health) ; Glimelius, Bengt (University of Uppsala) ; Harkin, Andrea (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences) ; Allan, Karen (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences) ; McQueen, John (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences) ; Pearson, Sarah (University of Oxford. Department of Oncology, OCTO) ; Waterston, Ashita (Beatson West of Scotland Cancer Centre) ; Medley, Louise (Royal United Hospital) ; Wilson, Charles (Addenbrookes Hospital (Cambridge, Regne Unit)) ; Ellis, Richard (Royal Cornwall Hospitals NHS Trust) ; Essapen, Sharadah (St Luke's Cancer Centre, Royal Surrey County Hospital NHS Foundation Trust) ; Dhadda, Amandeep S. (Castle Hill Hospital) ; Hughes, Rob (Mount Vernon Cancer Centre) ; Falk, Stephen (Bristol Cancer Institute, Bristol, UK) ; Raouf, Sherif (Barking Havering and Redbridge University Hospital NHS Trust, Barking, UK) ; Rees, Charlotte (Southampton University Hospital NHS Foundation Trust) ; Olesen, Rene K (Zealand University Hospital, Department of Oncology and Palliative Care, Rǻdmandsengen 5) ; Propper, David (Queen Mary, University of London. Barts Cancer Institute) ; Bridgewater, John (University College London) ; Azzabi, Ashraf (Newcastle upon Tyne Hospitals NHS Foundation Trust) ; Farrugia, David (Gloucestershire Oncology Centre, Cheltenham General Hospital) ; Webb, Andrew (Brighton and Sussex University Hospital Trust) ; Cunningham, David (Royal Marsden (funded by NIHR BRC at the Royal Marsden)) ; Hickish, Tamas (Poole Hospital/Bournemouth University) ; Weaver, Andrew (Churchill Hospital, Oxford University Hospitals Foundation Trust) ; Gollins, Simon (North Wales Cancer Treatment Centre, Rhyl, UK) ; Wasan, Harpreet S (Hammersmith Hospital, Imperial College London) ; Paul, James (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences)
The Short Course Oncology Therapy (SCOT) study is an international, multicentre, non-inferiority randomised controlled trial assessing the efficacy, toxicity, and cost-effectiveness of 3 months (3 M) versus the usually given 6 months (6 M) of adjuvant chemotherapy in colorectal cancer. [...]
2018 - 10.1038/s41416-018-0319-z
British Journal of Cancer, Vol. 119 (november 2018) , p. 1332-1338  
8.
11 p, 1.5 MB Mechanisms of inactivation of the tumour suppressor gene RHOA in colorectal cancer / Dopeso, Higinio (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Rodrigues, Paulo (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Bilic, Josipa (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Bazzocco, Sarah (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Cartón-García, Fernando (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Macaya, Irati (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; de Marcondes, Priscila Guimarães (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Anguita, Estefanía (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Masanas, Marc (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Jiménez-Flores, Lizbeth M (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Martínez-Barriocanal, Águeda (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Nieto, Rocío (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Segura, Miguel F (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Schwartz Jr, Simo (CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN)) ; Mariadason, John M (La Trobe University School of Cancer Medicine, Olivia Newton-John Cancer Research Institute) ; Arango, Diego (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Universitat Autònoma de Barcelona
Reduced RHOA signalling has been shown to increase the growth/metastatic potential of colorectal tumours. However, the mechanisms of inactivation of RHOA signalling in colon cancer have not been characterised. [...]
2017 - 10.1038/bjc.2017.420
British Journal of Cancer, Vol. 118 (december 2017) , p. 106-116  
9.
8 p, 196.5 KB Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer / Sclafani, Francesco (Department of Medicine, The Royal Marsden NHS Foundation Trust) ; Brown, Gina (Department of Radiology, The Royal Marsden NHS Foundation Trust) ; Cunningham, David (Department of Medicine, The Royal Marsden NHS Foundation Trust) ; Wotherspoon, Andrew (Department of Histopathology, The Royal Marsden NHS Foundation Trust) ; Mendes, Larissa Sena Teixeira (Department of Histopathology, The Royal Marsden NHS Foundation Trust) ; Balyasnikova, Svetlana (Department of Radiology, The Royal Marsden NHS Foundation Trust) ; Evans, Jessica (Department of Radiology, The Royal Marsden NHS Foundation Trust) ; Peckitt, Clare (Clinical Research & Development, The Royal Marsden NHS Foundation Trust) ; Begum, Ruwaida (Department of Medicine, The Royal Marsden NHS Foundation Trust) ; Tait, Diana (Department of Medicine, The Royal Marsden NHS Foundation Trust) ; Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ; Glimelius, Bengt (Department of Immunology, Genetics and Pathology, Section of Experimental and Clinical Oncology, University of Uppsala) ; Roselló, Susana (Department of Haematology and Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia) ; Thomas, Janet (Department of Medicine, The Royal Marsden NHS Foundation Trust) ; Oates, Jacqui (Department of Medicine, The Royal Marsden NHS Foundation Trust) ; Chau, Ian (Department of Medicine, The Royal Marsden NHS Foundation Trust)
Limited data exist regarding the correlation between MRI tumour regression grade (mrTRG) and pathological TRG (pTRG) in rectal cancer. mrTRG and pTRG were compared in rectal cancer patients from two phase II trials (EXPERT and EXPERT-C). [...]
2017 - 10.1038/bjc.2017.320
British Journal of Cancer, Vol. 117 (09 2017) , p. 1478-1485  
10.
12 p, 1.7 MB Ligand-dependent Hedgehog pathway activation in Rhabdomyosarcoma : the oncogenic role of the ligands / Almazán-Moga, A (Hospital Universitari Vall d'Hebron) ; Zarzosa, P (Hospital Universitari Vall d'Hebron) ; Molist, C (Hospital Universitari Vall d'Hebron) ; Velasco, Pablo (Universitat Autònoma de Barcelona. Departament de Pediatria, Obstetrícia i Ginecologia i Medicina Preventiva i Salut Pública) ; Pyczek, J (Institute of Human Genetics, University of Goettingen) ; Simon-Keller, K (Institute of Pathology, University Medical Centre Mannheim, University of Heidelberg) ; Giralt, Irina (Hospital Universitari Vall d'Hebron) ; Vidal, I (Hospital Universitari Vall d'Hebron) ; Navarro, N (Hospital Universitari Vall d'Hebron) ; Segura, M F (Hospital Universitari Vall d'Hebron) ; Soriano, A (Hospital Universitari Vall d'Hebron) ; Navarro, S (Universitat de València. Departament de Patologia) ; Tirado, O M (Institut d'Investigació Biomèdica de Bellvitge) ; Ferreres, J C (Hospital Universitari Vall d'Hebron) ; Santamaria, A (Hospital Universitari Vall d'Hebron) ; Rota, R (Ospedale Pediatrico Bambino Gesù, IRCCS) ; Hahn, H (Institute of Human Genetics, University of Goettingen) ; Sánchez de Toledo, J (Hospital Universitari Vall d'Hebron) ; Roma, J (Hospital Universitari Vall d'Hebron) ; Gallego, S (Hospital Universitari Vall d'Hebron)
Rhabdomyosarcoma (RMS) is the most common type of soft tissue sarcoma in children. The Hedgehog (HH) pathway is known to develop an oncogenic role in RMS. However, the molecular mechanism that drives activation of the pathway in RMS is not well understood. [...]
2017 - 10.1038/bjc.2017.305
British Journal of Cancer, Vol. 117 (09 2017) , p. 1314-1325  

Dipòsit Digital de Documents de la UAB : 23 registres trobats   1 - 10següentfinal  anar al registre:
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.